Highlights from

EAN 2019

European Academy of Neurology

Oslo 29 June - 2 July 2019

Novel solution of levodopa/carbidopa prodrugs via CSCI

ABBV-951 is a novel solution of levodopa and carbidopa prodrugs delivered via minimally invasive continuous subcutaneous infusion (CSCI). It was safe, generally well-tolerated, and did not cause notable skin reactions at low -yet clinically relevant- doses administered in a confined area of the abdomen continuously for 10 consecutive days [1].

A dose of ABBV-951 equivalent to ~600 mg of levodopa and an equal volume of saline were administered in two demarcated areas, 5 cm in diameter, on opposite sides of the abdomen of 34 healthy volunteers. Infusion sets were changed and reapplied daily on the same skin surface. There were no notable skin reactions in the ABBV-951 site, and only one in the placebo site. There was no significant difference between ABBV-951 and placebo in outcomes of dermatological assessment via the Infusion Site Evaluation scales (P=0.820; P=0.363). The most frequently reported adverse events were infusion site erythema (92%); infusion site reaction (44%); and infusion site pain (32%). All events were mild or moderate, and resolved quickly.

The authors proposed that ABBV-951 has the potential to provide the broad range of levodopa exposure required to adequately control motor symptoms and to be an alternative therapeutic option for PD patients. The results supported their phase 1b study of ABBV-951 delivered via CSCI in PD patients in an outpatient setting over 28 days. The primary objective will be to assess the local and systemic safety and tolerability of ABBV-951 [2]. Efficacy will also be explored.

  1. Facheris M, et al. EAN 2019, EPO1200.
  2. Facheris M, et al. EAN 2019, EPO1199.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.